Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BioHarvest Sciences ( (DE:8MV0) ) is now available.
BioHarvest Sciences reported a significant 62% increase in fourth-quarter revenues to $7.3 million and a 99% year-over-year growth to $25.2 million for the full year 2024, surpassing previous guidance. The company achieved a major milestone by securing a partnership with Tate & Lyle to develop plant-based sweeteners, validating its Botanical Synthesis platform. BioHarvest also expanded its VINIA® product line and successfully uplisted to the Nasdaq Global Market, positioning itself for further growth and operational efficiency improvements in 2025.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a company pioneering its patented Botanical Synthesis technology platform, focusing on the development of plant-based non-GMO biologic compounds for the pharmaceutical, nutraceutical, nutrition, and cosmetics industries. The company is also expanding its product portfolio in the plant-based nutraceuticals market with its VINIA® product lines.
Average Trading Volume: 1,114
Technical Sentiment Signal: Buy
Current Market Cap: C$137.8M
See more data about 8MV0 stock on TipRanks’ Stock Analysis page.